1
|
Bercu J, Trejo-Martin A, Chen C, Schuler M, Cheung J, Cheairs T, Lynch AM, Thomas D, Czich A, Atrakchi A, McGovern TJ, Heflich RH, Vespa A, Froetschl R, Yang Y, Gandhi RD, Elloway J, Ziegler V, Hellmann A, Schaefer M, Tennant RE, Westerink W, Hoffmans R, Jolly R, Noteboom J, Gollapudi P, Sobol Z, McGettigan KK, Christensen JS, Simon S, Dieckhoff J, Zeller A, Marchand C, Waese K, Bishop ME, Leavitt P, Hargreaves V, Glick C, Liao Y, Elespuru R, Puglisi R. HESI GTTC ring trial: Concordance between Ames and rodent carcinogenicity outcomes for N-nitrosamines (NAs) with rat and hamster metabolic conditions. Regul Toxicol Pharmacol 2025; 161:105835. [PMID: 40311791 DOI: 10.1016/j.yrtph.2025.105835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2025] [Revised: 04/14/2025] [Accepted: 04/26/2025] [Indexed: 05/03/2025]
Abstract
A multi-sector study (i.e., Ring Trial) was designed to improve the in vitro detection of N-nitrosamine (NA)-associated mutagenicity by optimizing the bacterial reverse mutation (i.e., Ames) assay protocol and testing various conditions on the sensitivity and specificity for the prediction of rodent carcinogenicity. A total of 29 NAs and 3 N-nitroso drug-like compounds from different structural classes and carcinogenicity outcomes were tested (two independent laboratories per compound) across 5 bacterial strains using a 30-min pre-incubation protocol. To evaluate the impact of different metabolic activating systems (MASs), testing conditions included the use of 10 or 30 % liver S9 fractions prepared from rats or hamsters pretreated with inducers of enzymatic activity. Results indicate that E. coli and Salmonella typhimurium strains detecting single base pair mutations, coupled with MASs containing 30 % hamster S9s were the most sensitive (90 %) for identifying NAs that are rodent carcinogens. Regarding MAS combinations, the highest sensitivity was 30 % rat and 30 % hamster (93 %), but has low specificity (45 %), with good laboratory agreement for the Ames calls (91 %). DMSO and water were considered suitable solvents, except for small-molecular weight alkyl NAs. These results will support harmonized Ames testing of NAs, giving high confidence for a negative result.
Collapse
Affiliation(s)
- Joel Bercu
- Gilead Sciences, Inc., Nonclinical Safety and Pathobiology, Foster City, CA, 94404, USA
| | | | - Connie Chen
- Health and Environmental Sciences Institute, Washington, DC, 20005, USA
| | - Maik Schuler
- Pfizer Research, Development, and Medical, Groton, CT, 06370, USA
| | - Jennifer Cheung
- Pfizer Research, Development, and Medical, Groton, CT, 06370, USA
| | - Tetyana Cheairs
- New York Medical College, Department of Pathology, Microbiology and Immunology, Valhalla, NY, 10595, USA
| | - Anthony M Lynch
- GSK, Genetic & Investigative Toxicology, Stevenage, Hertfordshire, UK
| | - Dean Thomas
- GSK, Genetic & Investigative Toxicology, Stevenage, Hertfordshire, UK
| | - Andreas Czich
- Sanofi, R&D Translational Medicine Preclinical Safety, D-69526, Frankfurt, Germany
| | - Aisar Atrakchi
- US Food and Drug Administration/Center for Drug Evaluation and Research, Silver Spring, MD, 20993, USA
| | - Timothy J McGovern
- US Food and Drug Administration/Center for Drug Evaluation and Research, Silver Spring, MD, 20993, USA
| | - Robert H Heflich
- US Food and Drug Administration/National Center for Toxicological Research, AR, USA
| | - Alisa Vespa
- Pharmaceutical Drugs Directorate, Health Canada, Ottawa, Ontario, Canada
| | - Roland Froetschl
- BfArM Federal Institute for Drugs and Medical Devices, Genetic and Reproductive Toxicology, Bonn, 53175, Germany
| | - Yi Yang
- AbbVie Inc., Global Preclinical Safety, Chicago, IL, 60064, USA
| | - Raj D Gandhi
- Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK
| | - Joanne Elloway
- Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK
| | - Verena Ziegler
- Bayer AG - Pharmaceuticals, In vitro Safety, 13342, Berlin, Germany
| | - Anna Hellmann
- Global Nonclinical Safety & DMPK, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
| | - Michelle Schaefer
- Global Nonclinical Safety & DMPK, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 06877, USA
| | | | | | - Roy Hoffmans
- Charles River Laboratories, Den Bosch, the Netherlands
| | - Robert Jolly
- Eli Lilly and Company, Indianapolis, IN, 46285, USA
| | | | | | - Zhanna Sobol
- Nonclinical Drug Safety, MRL, Merck & Co., Inc., Rahway, NJ, USA
| | | | | | | | | | | | | | - Kerstin Waese
- Sanofi, R&D Translational Medicine Preclinical Safety, D-69526, Frankfurt, Germany
| | - Michelle E Bishop
- US Food and Drug Administration/National Center for Toxicological Research, AR, USA
| | | | | | | | - Yang Liao
- Cencora PharmaLex, Conshohocken, PA, 19428, USA
| | - Rosalie Elespuru
- US Food and Drug Administration/Center for Medical Devices (retired), Annapolis, MD, 21403, USA
| | - Raechel Puglisi
- Health and Environmental Sciences Institute, Washington, DC, 20005, USA.
| |
Collapse
|